DOCSLIB.ORG

14.30 Dr Hector Chinoy

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

Recent advances in myositis Dr Hector Chinoy PhD FRCP @drhectorchinoy Senior Lecturer / Honorary Consultant Rheumatologist Salford Royal NHS Foundation Trust Manchester Academic Health Science Centre The University of Manchester, UK Planned Layout what is myositis? how do we classify myositis? myositis disease spectrum antibodies case presentations how do we assess and treat myositis? Planned Layout what is myositis? how do we classify myositis? myositis disease spectrum antibodies case presentations how do we assess and treat myositis? Idiopathic inflammatory myopathy (IIM): A heterogeneous group of rare autoimmune muscle disorders Rare disease, annual Different IIM subtypes with incidence 5-10/million commonality of myositis 2 peaks of onset: Extra - muscular features (5-15 years) eg skin, lung, cardiac, (30-50 years) malignancy Patterns of disease Lack of evidence base for (rule of 1/3’s): treatment Monogenic Steroid & immunoresponsive Relapsing/remitting Treatment phases: induction/maintenance of remission Chronic persistent How do patients’ present with inflammatory myopathy? Insidious onset of proximal weakness Myalgia Fatigue Dysphagia Dyspnoea Weight loss Skin abnormalities (including ulceration) Raynaud’s Dry, cracked hands Arthralgia/arthritis Creatine Features of Myositis ATP ATP Creatine Kinase + ADP ADP + H Creatine phosphate Clues on bloods Low creatinine High ferritin High ALT Raised Troponin T Negative ANA Many causes of raised CK! 1. Muscle trauma a) Muscle injury / Needle stick b) EMG c) Surgery d) Convulsions, delirium tremens 2. Diseases affecting muscle a) Myocardial infarction f) Dystrophinopathies b) Rhabdomyolysis h) Amyotrophic lateral sclerosis g) Infectious myositis i) Neuromyotonias c) Metabolic myopathies h) Idiopathic inflammatory d) Carnitine palmityltransferase myopathy II deficiency e) Mitochondrial myopathies 3. Drug/toxin-induced a) Lipid-lowering agents, especially statins myopathy b) Alcoholic myopathy c) Drugs of abuse: e.g. cocaine, amphetamines, phencyclidine d) Malignant hyperthermia / neuroleptic malignant syndrome e) Other meds: e.g. zidovudine, colchicine, chloroquine, ipecac 4. Drug-induced CK elevation Inhibition of excretion: e.g. barbiturates, morphine, diazepam 5. Endocrine and metabolic a) Hypothyroidism abnormalities b) Hypokalemia c) Hyperosmolar state or ketoacidosis d) Diabetic nephrotic syndrome with oedema e) Renal failure 6. Elevation without disease a) Strenuous, prolonged, and/or unaccustomed exercise b) Ethnic group (black > white) c) Increased muscle mass Adapted from Targoff 2002 Differential diagnosis of muscle weakness Inherited myopathies Muscular dystrophies: Duchenne’s, fascioscapulohumeral, limb girdle, Becker’s, Emery Dreifuss, distal, ocular Congenital myopathies: nemaline, mitochondrial, centronuclear, central core Neurologic Denervating conditions: spinal muscular atrophies, amyotrophic lateral sclerosis Neuromuscular junction disorders: Eaton-Lambert syndrome, myasthenia gravis Myotonic disease: dystrophia myotonica, myotonia congenita, PROMM Other: Guillain-Barre syndrome, chronic autoimmune polyneuropathy Metabolic Glycogen storage diseases: acid maltase deficiency, McArdle’s, PFK Lipid storage myopathies: carnitine palmityltransferase II deficiency Nutritional: vitamin E deficiency, malabsorption Other: uraemia, hepatic failure, alcoholism, acute intermittent porphyria, diabetic plexopathy Endocrine Hyper/hypothyroidism, acromegaly, Cushing’s syndrome, Addison’s disease, myopathies vitamin D deficiency, hyper/hypocalcaemia, hypokalaemia Drug-induced Statins, D-penicillamine, clofibrate, chloroquine, amiodarone, vincristine, zidovudine myopathies Infections Acute viral: influenza, hep B, echovirus, rickettsia, coxsackie, rubella, vaccines Bacterial pyomyositis: staphylococcus, streptococcus, clostridium perfringens, leprosy Parasites: toxoplasma, trichinella, schistosoma, cysticercus Other CTDs Rheumatoid arthritis, systemic sclerosis, systemic lupus erythematosus Miscellaneous Periodic paralyses, carcinomatous neuromyopathy, acute rhabdomyolysis, myositis ossificans, microembolisation by atheroma or carcinoma Oddis CV, Rheum Dis Clin North Am 2002;28:979-1001 what is myositis? how do we classify myositis? myositis disease spectrum antibodies case presentations how do we assess and treat myositis? Polymyositis Necrotizing Myopathy Dermatomyositis Inclusion Body Myositis Idiopathic Malignancy Inflammatory Myopathy Myositis-CTD overlap Juvenile dermatomyositis Bohan and Peter diagnostic criteria for polymyositis / dermatomyositis 1 Symmetrical weakness of limb-girdle muscles and anterior neck flexors 2 Muscle biopsy evidence typical of myositis 3 Elevation of serum skeletal muscle enzymes, particularly CK 4 Typical EMG features of myositis 5 Typical DM rash, including heliotrope and Gottron’s papules For the diagnosis of PM: For the diagnosis of DM: Definite: All of items 1-4 Definite: Item 5 plus 3 of items 1-4 . Probable: 3 of items 1-4 Probable: Item 5 plus 2 of items 1-4 Possible: 2 of items 1-4 Possible: Item 5 plus 1 of items 1-4 Exclusion criteria: congenital muscular dystrophies, central or peripheral neurological disease, infectious myositis, metabolic/endocrine myopathies and myasthenia gravis. Bohan A, Peter JB, N Eng J Med 1975 New classification criteria for myositis Tjarnlund et al, Ann Rheum Dis 2013 Vol 72, suppl 3, p60 http://www.imm.ki.se/ biostatistics/calculators/iim/ Extra-muscular features of Inflammatory Myopathy Hughes M, Lilleker JB, Herrick AL, Chinoy H. Cardiac troponin testing in idiopathic inflammatory myopathies and systemic sclerosis-spectrum disorders: biomarkers to distinguish between primary cardiac involvement and low-grade skeletal muscle disease activity. Slides courtesy of IMACS, Prof Oddis & McHugh Ann Rheum Dis. 2015 May;74(5):795-8 http://www.cytoskeleton.com/tropomyosin-troponin-complex-cs-tt05 Myositis: effects of muscle damage Photo courtesy of Prof R Cooper Heliotrope rash Violaceous to erythematous discrete or confluent macules confined to the upper eyelids Gottron’s papules Erythematous to violaceous papules and plaques over the extensor surfaces of MCP and IP joints & other large joints in a symmetric distribution Nail changes V / Shawl sign Discrete, confluent macular erythema over lower anterior neck, upper anterior chest & shawl distribution V SIGN SHAWL SIGN what is myositis? how do we classify myositis? myositis disease spectrum antibodies case presentations how do we assess and treat myositis? Myositis-Spectrum Disease Autoantibodies Autoantibody formation HLA Other genes Specific signs Infections & symptoms UV Environmental risk factors Slide adapted from Dr Gunawardena Hood E: Environ Health Perspect 2003, 111:A274–A276. Always worth Checking ANA pattern for clues Gunawardena H. The Clinical Features of Myositis-Associated Autoantibodies: a Review. Clin Rev Allergy Immunol. 2017 Feb;52(1):45-57. Myositis Spectrum Disease Antibodies & Clinical Associations in Adult Myositis Betteridge Z, McHugh N. Myositis-specific autoantibodies: an important tool to support diagnosis of myositis. J Intern Med. 2016 Jul;280(1):8-23 Anti-synthetase / anti-PM-Scl: Remember Interstitial Lung Disease Jo-1: anti-synthetase syndrome PM-Scl: myositis/scleroderma overlap syndrome Pictures courtesy of Drs Herrick, Oddis & Wedderburn Anti-synthetase / anti-PM-Scl: Remember Interstitial Lung Disease Jo-1: anti-synthetase syndrome REMEMBER - PATIENTS MAY PRESENT WITHOUT CLINICAL MYOSITIS PM-Scl: myositis/scleroderma overlap syndrome Pictures courtesy of Drs Herrick, Oddis & Wedderburn Anti-MDA5 (anti-CADM140) Reported Clinical Associations ILD (67-100%) Rapidly Progressing ILD (RP-ILD) (22- 100%) Skin manifestations Gottron’s Papules Periungal Ulceration (skin and mouth) Hand Swelling Arthritis JDM Associations Palmar Papules Skin and Oral Ulcers Mechanics’ Hands No known association with Periungal, Gottron’s Papules, Arthritis or Alopecia Panniculitis ILD? AlopeciaFiorentino et al J Am Acad Dermatol 2011;65:25-34 Sato et al Arthritis Rheum 2005;52:1571-6 Nakashima et al Rheumatol 2010;49:433-40 Slide adapted from Dr Betteridge Kobayashi et al J Pediatr 2011;158:675-7 Anti-TIF1g: diagnostic utility in cancer associated myositis Pooled sensitivity for cancer-associated myositis SENSITIVITY SPECIFICITY 0.78 0.89 Trallero-Araguás et al, Arthritis Rheum 2012;64:523–532 what is myositis? how do we classify myositis? myositis disease spectrum antibodies case presentations how do we assess and treat myositis? Case 1: Mrs SH • 57 year old female, type II DM • 1 year post-simvastatin • 3 month history of marked proximal weakness • CK 11,384 • EMG: fibrillations & brief duration simple and complex motor unit potentials MR images T1 STIR Muscle biopsy H&E stained section showing necrotic fibres with macrophage infiltrates Clinical features of anti-HMG CoA reductase (HMGCR) positive patients (45/750, 6%) Features Anti-HMGCR Ab not found Age 52 ± 16 years in majority of statin- treated subjects, including Female 58% those with self-limited Statin exposure 30/45 (67%) statin-associated myopathy (24/26, 92% >50 years) CPK 9,718 ± 7,383 iu/l Strong HLA association Cases v controls analysis (41:164) Proximal weakness 96% HLA-DRB1*11 Irritable EMG 73% p=4.29X10-5, OR=5.60, 95% CI=2.62-12.63 (unpublished data, our lab) Necrosis on biopsy 100% Inflammation on 20% biopsy Mammen A et al. Arthritis Rheum 2011;63:713-721 Mammen A et al. Arthritis Care Res (Hoboken). 2012;64:269-72 Statin-related myotoxicity phenotype classification Alfirevic
Recommended publications
  • The Role of Z-Disc Proteins in Myopathy and Cardiomyopathy

    The Role of Z-Disc Proteins in Myopathy and Cardiomyopathy

    International Journal of Molecular Sciences Review The Role of Z-disc Proteins in Myopathy and Cardiomyopathy Kirsty Wadmore 1,†, Amar J. Azad 1,† and Katja Gehmlich 1,2,* 1 Institute of Cardiovascular Sciences, College of Medical and Dental Sciences, University of Birmingham, Birmingham B15 2TT, UK; [email protected] (K.W.); [email protected] (A.J.A.) 2 Division of Cardiovascular Medicine, Radcliffe Department of Medicine and British Heart Foundation Centre of Research Excellence Oxford, University of Oxford, Oxford OX3 9DU, UK * Correspondence: [email protected]; Tel.: +44-121-414-8259 † These authors contributed equally. Abstract: The Z-disc acts as a protein-rich structure to tether thin filament in the contractile units, the sarcomeres, of striated muscle cells. Proteins found in the Z-disc are integral for maintaining the architecture of the sarcomere. They also enable it to function as a (bio-mechanical) signalling hub. Numerous proteins interact in the Z-disc to facilitate force transduction and intracellular signalling in both cardiac and skeletal muscle. This review will focus on six key Z-disc proteins: α-actinin 2, filamin C, myopalladin, myotilin, telethonin and Z-disc alternatively spliced PDZ-motif (ZASP), which have all been linked to myopathies and cardiomyopathies. We will summarise pathogenic variants identified in the six genes coding for these proteins and look at their involvement in myopathy and cardiomyopathy. Listing the Minor Allele Frequency (MAF) of these variants in the Genome Aggregation Database (GnomAD) version 3.1 will help to critically re-evaluate pathogenicity based on variant frequency in normal population cohorts.
  • Current and Emerging Therapies in Becker Muscular Dystrophy (BMD)

    Current and Emerging Therapies in Becker Muscular Dystrophy (BMD)

    Acta Myologica • 2019; XXXVIII: p. 172-179 OPEN ACCESS © Gaetano Conte Academy - Mediterranean Society of Myology Current and emerging therapies in Becker muscular dystrophy (BMD) Corrado Angelini, Roberta Marozzo and Valentina Pegoraro Neuromuscular Center, IRCCS San Camillo Hospital, Venice, Italy Becker muscular dystrophy (BMD) has onset usually in child- tients with a deletion in the dystrophin gene that have nor- hood, frequently by 11 years. BMD can present in several ways mal muscle strength and endurance, but present high CK, such as waddling gait, exercise related cramps with or with- and so far their follow-up and treatment recommenda- out myoglobinuria. Rarely cardiomyopathy might be the pre- senting feature. The evolution is variable. BMD is caused by tions are still a matter of debate. Patients with early cardi- dystrophin deficiency due to inframe deletions, mutations or omyopathy are also a possible variant of BMD (4, 5) and duplications in dystrophin gene (Xp21.2) We review here the may be susceptible either to specific drug therapy and/or evolution and current therapy presenting a personal series of to cardiac transplantation (6-8). Here we cover emerging cases followed for over two decades, with multifactorial treat- therapies considering follow-up, and exemplifying some ment regimen. Early treatment includes steroid treatment that phenotypes and treatments by a few study cases. has been analized and personalized for each case. Early treat- ment of cardiomyopathy with ACE inhibitors is recommended and referral for cardiac transplantation is appropriate in severe cases. Management includes multidisciplinary care with physi- Pathophysiology and rationale of otherapy to reduce joint contractures and prolong walking.
  • Myositis Center Myositis Center

    Myositis Center Myositis Center

    About The Johns Hopkins The Johns Hopkins Myositis Center Myositis Center he Johns Hopkins Myositis Center, one Tof the first multidisciplinary centers of its kind that focuses on the diagnosis and management of myositis, combines the ex - pertise of rheumatologists, neurologists and pulmonologists who are committed to the treatment of this rare disease. The Center is conveniently located at Johns Hopkins Bayview Medical Center in Baltimore, Maryland. Patients referred to the Myositis Center can expect: • Multidisciplinary Care: Johns Hopkins Myositis Center specialists make a diagno - sis after evaluating each patient and re - viewing results of tests that include muscle enzyme levels, electromyography, muscle biopsy, pulmonary function and MRI. The Center brings together not only physicians with extensive experience in di - agnosing, researching and treating myosi - tis, but nutritionists and physical and occupational therapists as well. • Convenience: Same-day testing and appointments with multiple specialists are The Johns Hopkins typically scheduled to minimize doctor Myositis Center visits and avoid delays in diagnosis and Johns Hopkins Bayview Medical Center treatment. Mason F. Lord Building, Center Tower 5200 Eastern Avenue, Suite 4500 • Community: Because myositis is so rare, Baltimore, MD 21224 the Center provides a much-needed oppor - tunity for patients to meet other myositis patients, learn more about the disease and Physician and Patient Referrals: 410-550-6962 be continually updated on breakthroughs Fax: 410-550-3542 regarding treatment options. www.hopkinsmedicine.org/myositis The Johns Hopkins Myositis Center THE CENTER BRINGS TOGETHER Team NOT ONLY PHYSICIANS WITH EXTENSIVE EXPERIENCE IN DIAGNOSING , RESEARCHING AND Lisa Christophe r-Stine, TREATING MYOSITIS , BUT M.D., M.P.H.
  • Focal Eosinophilic Myositis Presenting with Leg Pain and Tenderness

    Focal Eosinophilic Myositis Presenting with Leg Pain and Tenderness

    CASE REPORT Ann Clin Neurophysiol 2020;22(2):125-128 https://doi.org/10.14253/acn.2020.22.2.125 ANNALS OF CLINICAL NEUROPHYSIOLOGY Focal eosinophilic myositis presenting with leg pain and tenderness Jin-Hong Shin1,2, Dae-Seong Kim1,2 1Department of Neurology, Research Institute for Convergence of Biomedical Research, Pusan National University Yangsan Hospital, Yangsan, Korea 2Department of Neurology, Pusan National University School of Medicine, Yangsan, Korea Focal eosinophilic myositis (FEM) is the most limited form of eosinophilic myositis that com- Received: September 11, 2020 monly affects the muscles of the lower leg without systemic manifestations. We report a Revised: September 29, 2020 patient with FEM who was studied by magnetic resonance imaging and muscle biopsy with Accepted: September 29, 2020 a review of the literature. Key words: Myositis; Eosinophils; Magnetic resonance imaging Correspondence to Dae-Seong Kim Eosinophilic myositis (EM) is defined as a group of idiopathic inflammatory myopathies Department of Neurology, Pusan National associated with peripheral and/or intramuscular eosinophilia.1 Focal eosinophilic myositis Univeristy School of Medicine, 20 Geu- mo-ro, Mulgeum-eup, Yangsan 50612, (FEM) is the most limited form of EM and is considered a benign disorder without systemic 2 Korea manifestations. Here, we report a patient with localized leg pain and tenderness who was Tel: +82-55-360-2450 diagnosed as FEM based on laboratory findings, magnetic resonance imaging (MRI), and Fax: +82-55-360-2152 muscle biopsy. E-mail: [email protected] ORCID CASE Jin-Hong Shin https://orcid.org/0000-0002-5174-286X A 26-year-old otherwise healthy man visited our outpatient clinic with leg pain for Dae-Seong Kim 3 months.
  • A Acanthosis Nigricans, 139 Acquired Ichthyosis, 53, 126, 127, 159 Acute

    A Acanthosis Nigricans, 139 Acquired Ichthyosis, 53, 126, 127, 159 Acute

    Index A Anti-EJ, 213, 214, 216 Acanthosis nigricans, 139 Anti-Ferc, 217 Acquired ichthyosis, 53, 126, 127, 159 Antigliadin antibodies, 336 Acute interstitial pneumonia (AIP), 79, 81 Antihistamines, 324 Adenocarcinoma, 115, 116, 151, 173 Anti-histidyl-tRNA-synthetase antibody Adenosine triphosphate (ATP), 229 (Anti-Jo-1), 6, 14, 140, 166, 183, Adhesion molecules, 225–226 213–216 Adrenal gland carcinoma, 115 Anti-histone antibodies (AHA), 174, 217 Age, 30–32, 157–159 Anti-Jo-1 antibody syndrome, 34, 129 Alanine aminotransferase (ALT, ALAT), 16, Anti-Ki-67 antibody, 247 128, 205, 207, 255 Anti-KJ antibodies, 216–217 Alanyl-tRNA synthetase, 216 Anti-KS, 82 Aldolase, 14, 16, 128, 129, 205, 207, 255, 257 Anti-Ku antibodies, 163, 165, 217 Aledronate, 325 Anti-Mas, 217 Algorithm, 256, 259 Anti-Mi-2 Allergic contact dermatitis, 261 antibody syndrome, 11, 129, 215 Alopecia, 62, 199, 290 antibodies, 6, 15, 129, 142, 212 Aluminum hydroxide, 325, 326 Anti-Myo 22/25 antibodies, 217 Alzheimer’s disease-related proteins, 190 Anti-Myosin scintigraphy, 230 Aminoacyl-tRNA synthetases, 151, 166, 182, Antineoplastic agents, 172 212, 215 Antineoplastic medicines, 169 Aminoquinolone antimalarials, 309–310, 323 Antinuclear antibody (ANA), 1, 141, 152, 171, Amyloid, 188–190 172, 174, 213, 217 Amyopathic DM, 6, 9, 29–30, 32–33, 36, 104, Anti-OJ, 213–214, 216 116, 117, 147–153 Anti-p155, 214–215 Amyotrophic lateral sclerosis, 263 Antiphospholipid syndrome (APS), 127, Antisynthetase syndrome, 11, 33–34, 81 130, 219 Anaphylaxi, 316 Anti-PL-7 antibody, 82, 214 Anasarca,
  • Muscle Biopsy Features of Idiopathic Inflammatory Myopathies And

    Muscle Biopsy Features of Idiopathic Inflammatory Myopathies And

    Autoimmun Highlights (2014) 5:77–85 DOI 10.1007/s13317-014-0062-2 REVIEW ARTICLE Muscle biopsy features of idiopathic inflammatory myopathies and differential diagnosis Gaetano Vattemi • Massimiliano Mirabella • Valeria Guglielmi • Matteo Lucchini • Giuliano Tomelleri • Anna Ghirardello • Andrea Doria Received: 1 August 2014 / Accepted: 22 August 2014 / Published online: 10 September 2014 Ó Springer International Publishing Switzerland 2014 Abstract The gold standard to characterize idiopathic Keywords Inflammatory myopathy Á Autoimmune inflammatory myopathies is the morphological, immuno- myositis Á Histopathology Á Differential diagnosis histochemical and immunopathological analysis of muscle biopsy. Mononuclear cell infiltrates and muscle fiber necrosis are commonly shared histopathological features. Introduction Inflammatory cells that surround, invade and destroy healthy muscle fibers expressing MHC class I antigen are Idiopathic inflammatory myopathies (IIM) are a heteroge- the typical pathological finding of polymyositis. Perifas- neous group of acquired muscle diseases, which have dis- cicular atrophy and microangiopathy strongly support a tinct clinical, pathological and histological features [1, 2]. diagnosis of dermatomyositis. Randomly distributed The most common IIM seen in clinical practice can be necrotic muscle fibers without mononuclear cell infiltrates separated into four categories including polymyositis (PM), represent the histopathological hallmark of immune-med- dermatomyositis (DM), immune-mediated necrotizing iated necrotizing myopathy; meanwhile, endomysial myopathy (NM) and sporadic inclusion body myositis inflammation and muscle fiber degeneration are the two (sIBM) [1, 3]. main pathological features in sporadic inclusion body In the diagnostic workup of an inflammatory myopathy, myositis. A correct differential diagnosis requires immu- muscle biopsy is an indispensable and sensitive tool for nopathological analysis of the muscle biopsy and has establishing the diagnosis.
  • The Impact of Hypermobility Spectrum Disorders on Musculoskeletal Tissue Stiffness: an Exploration Using Strain Elastography

    The Impact of Hypermobility Spectrum Disorders on Musculoskeletal Tissue Stiffness: an Exploration Using Strain Elastography

    Clinical Rheumatology (2019) 38:85–95 https://doi.org/10.1007/s10067-018-4193-0 ORIGINAL ARTICLE The impact of hypermobility spectrum disorders on musculoskeletal tissue stiffness: an exploration using strain elastography Najla Alsiri1 & Saud Al-Obaidi2 & Akram Asbeutah2 & Mariam Almandeel1 & Shea Palmer3 Received: 24 January 2018 /Revised: 13 June 2018 /Accepted: 26 June 2018 /Published online: 3 July 2018 # International League of Associations for Rheumatology (ILAR) 2018 Abstract Hypermobility spectrum disorders (HSDs) are conditions associated with chronic joint pain and laxity. HSD’s diagnostic approach is highly subjective, its validity is not well studied, and it does not consider many of the most commonly affected joints. Strain elastography (SEL) reflects musculoskeletal elasticity with sonographic images. The study explored the impact of HSD on musculoskeletal elasticity using SEL. A cross-sectional design compared 21 participants with HSD against 22 controls. SEL was used to assess the elasticity of the deltoid, biceps brachii, brachioradialis, rectus femoris, and gastrocnemius muscles, and the patellar and Achilles tendon. SEL images were analyzed using strain index, strain ratio, and color pixels. Mean strain index (standard deviation) was significantly reduced in the HSD group compared to the control group in the brachioradialis muscle 0.43 (0.10) vs. 0.59 (0.24), patellar 0.30 (0.10) vs. 0.44 (0.11), and Achilles tendons 0.24 (0.06) vs. 0.49 (0.13). Brachioradialis muscle and patellar tendon’s strain ratios were significantly lower in the HSD group compared to the control group, 6.02 (2.11) vs. 8.68 (2.67) and 5.18 (1.67) vs.
  • Nemaline MYOPATHY Myopathy

    Nemaline MYOPATHY Myopathy

    NEMALINENemaline MYOPATHY Myopathy due to chest muscle weakness, feeding and swallowing What is nemaline myopathy? problems, and speech difficulties. Often, children with the condition have an elongated face and a Nemaline myopathy (NM) is a group of high arched palate. rare, inherited conditions that affect muscle tone and strength. It is also What causes nemaline myopathy? The condition can be caused by a mutation in one known as rod body disease because of several different genes that are responsible for at a microscopic level, abnormal making muscle protein. Most cases of nemaline rod-shaped bodies (nemalines) can myopathy are inherited, although there are some- be seen in affected muscle tissue. times sporadic cases. People with a family history may choose to undergo genetic counseling to help At various stages in life, the muscles of understand the risks of passing the gene on to their the shoulders, upper arms, pelvis and children. thighs may be affected. Symptoms usually start anywhere from birth to What are the types of nemaline myopathy? There are two main groups of nemaline myopathy: early childhood. In rare cases, it is ‘typical’ and ‘severe.’ Typical nemaline myopathy diagnosed during adulthood. NM is the most common form, presenting usually in affects an estimated 1 in 50,000 infants with muscle weakness and floppiness. It may people -- both males and females. be slowly progressive or non progressive, and most adults are able to walk. Severe nemaline myopathy is characterized by absence of spontaneous movement What are the symptoms? or respiration at birth, and often leads to death in Symptoms vary depending on the age of onset of the first months of life.
  • Eosinophilic Fasciitis: Typical Abnormalities

    Eosinophilic Fasciitis: Typical Abnormalities

    Diagnostic and Interventional Imaging (2015) 96, 341—348 REVIEW /Muskuloskeletal imaging Eosinophilic fasciitis: Typical abnormalities, variants and differential diagnosis of fasciae abnormalities using MR imaging a,∗ b,c a T. Kirchgesner , B. Dallaudière , P. Omoumi , a a a J. Malghem , B. Vande Berg , F. Lecouvet , d e a F. Houssiau , C. Galant , A. Larbi a Service de radiologie, Département d’imagerie musculo-squelettique, Cliniques Universitaires Saint-Luc, avenue Hippocrate 10-1200, Brussels, Belgium b Département d’imagerie, centre hospitalier universitaire Pellegrin, place Amélie-Léon-Rabat, 33000 Bordeaux, France c Clinique du sport de Bordeaux-Mérignac, 2, rue Négrevergne, 33700 Mérignac, France d Service de Rhumatologie, Cliniques Universitaires Saint-Luc, avenue Hippocrate 10-1200 Brussels, Belgium e Service d’anatomo-pathologie, Cliniques Universitaires Saint-Luc, avenue Hippocrate 10-1200, Brussels, Belgium KEYWORDS Abstract Eosinophilic fasciitis is a rare condition. It is generally limited to the distal parts of Fascia; the arms and legs. MRI is the ideal imaging modality for diagnosing and monitoring this condi- Fasciitis; tion. MRI findings typically evidence only fascial involvement but on a less regular basis signal Eosinophilic; abnormalities may be observed in neighboring muscle tissue and hypodermic fat. Differential Shulman; diagnosis of eosinophilic fasciitis by MRI requires the exclusion of several other superficial and MRI deep soft tissue disorders. © 2015 Éditions franc¸aises de radiologie. Published by Elsevier Masson SAS. All rights reserved. Eosinophilic fasciitis is a rare condition that was first described by Shulman in 1974 [1]. Magnetic resonance imaging (MRI) is the ideal imaging modality both for diagnosing and monitoring this condition. MRI examination typically evidences only fascial involvement but on a less regular basis signal abnormalities may be observed in neighboring muscle tissue and hypodermic fat.
  • Clinical Exome Sequencing for Genetic Identification of Rare Mendelian Disorders

    Clinical Exome Sequencing for Genetic Identification of Rare Mendelian Disorders

    Supplementary Online Content Lee H, Deignan JL, Dorrani N, Strom SP, Kantarci S, Quintero-Rivera F, et al. Clinical exome sequencing for genetic identification of rare Mendelian disorders. JAMA. doi:10.1001/jama.2014.14604. eMethods 1. Sample acquisition and pre-test sample processing eMethods 2. Exome capture and sequencing eMethods 3. Sequence data analysis eMethods 4. Variant filtration and interpretation eMethods 5. Determination of variant pathogenicity eFigure 1. UCLA Clinical Exome Sequencing (CES) workflow eFigure 2. Variant filtration workflow starting with ~21K variants across the exome and comparing the mean number of variants observed from trio-CES versus proband-CES eFigure 3. Variant classification workflow for the variants found within the primary genelist (PGL) eTable 1. Metrics used to determine the adequate quality of the sequencing test for each sample eTable 2. List of molecular diagnoses made eTable 3. List of copy number variants (CNVs) and uniparental disomy (UPD) reported and confirmatory status eTable 4. Demographic summary of 814 cases eTable 5. Molecular Diagnosis Rate of Phenotypic Subgroups by Age Group for Other Clinical Exome Sequencing References © 2014 American Medical Association. All rights reserved. Downloaded From: https://jamanetwork.com/ on 10/01/2021 This supplementary material has been provided by the authors to give readers additional information about their work. © 2014 American Medical Association. All rights reserved. Downloaded From: https://jamanetwork.com/ on 10/01/2021 eMethods 1. Sample acquisition and pre-test sample processing. Once determined by the ordering physician that the patient's presentation is clinically appropriate for CES, patients were offered the test after a counseling session ("pre-test counseling") [eFigure 1].
  • Inclusion Body Myositis: a Case with Associated Collagen Vascular Disease Responding to Treatment

    Inclusion Body Myositis: a Case with Associated Collagen Vascular Disease Responding to Treatment

    J Neurol Neurosurg Psychiatry: first published as 10.1136/jnnp.48.3.270 on 1 March 1985. Downloaded from Journal ofNeurology, Neurosurgery, and Psychiatry 1985;48:270-273 Short report Inclusion body myositis: a case with associated collagen vascular disease responding to treatment RJM LANE, JJ FULTHORPE, P HUDGSON UK From the Regional Neurological Centre, Newcastle General Hospital, Newcastle-upon-Tyne, elec- SUMMARY Patients with inclusion body myositis demonstrate characteristic histological and muscle and are generally considered refractory to treatment. tronmicroscopical abnormalities in autoimmune A patient with inclusion body myositis is described with evidence of associated disease, who responded to steroids. muscles. He felt that his legs were quite normal. He denied guest. Protected by copyright. The diagnosis of inclusion body myositis depends symptoms. There was no relevant family or of the characteristic any sensory ultimately on the demonstration drug history. dis- intracytoplasmic and intranuclear filamentous inclu- On examination, he had a prominent bluish/purple sions, and cytoplasmic vacuoles originally described colouration of the knuckles, thickening of the skin on the by Chou in 1968.' However, reviews of reported dorsum of the hands and a slight heliotrope facial rash. The features which facial muscles were slightly wasted and he had marked cases have also emphasised clinical sternomastoids, deltoids, appear to distinguish inclusion body myositis from weakness and wasting of the Prominent among spinatti, biceps and triceps, with relative preservation of other forms of polymyositis.2-7 distal muscles. All upper limb reflexes were grossly these are the lack of associated skin changes or other bulk, power and to diminished or absent.
  • NEUROLOGY NEUROSURGERY & PSYCHIATRY Editorial

    NEUROLOGY NEUROSURGERY & PSYCHIATRY Editorial

    Journal ofNeurology, Neurosurgery, and Psychiatry 1991;54:285-287 285 J Neurol Neurosurg Psychiatry: first published as 10.1136/jnnp.54.4.285 on 1 April 1991. Downloaded from Joural of NEUROLOGY NEUROSURGERY & PSYCHIATRY Editorial The idiopathic inflammatory myopathies and their treatment The inflammatory myopathies are the largest group of As new knowledge has accumulated over the course of acquired myopathies of adult life and may also occur in the last 10 years, it has become increasingly clear that there infancy and childhood. They have in common the presence are distinct pathological and immunological differences of inflammatory infiltrates within skeletal muscle, usually between polymyositis on the one hand and dermato- in association with muscle fibre destruction. They can be myositis on the other, though in some cases there is clearly subdivided into those which are due to known viral, an overlap between the two conditions. In polymyositis bacterial, protozoal or other microbial agents and those in there is usually scattered necrosis of single muscle fibres which no such agent can be identified and in which which appear hyalinised in the early stages and are immunological mechanisms have been implicated.' The subsequently invaded by mononuclear phagocytic cells. latter group includes polymyositis, dermatomyositis and Regenerating fibres are usually seen singly or in small inclusion body myositis. The evidence for an autoimmune groups distributed focally and randomly throughout the aetiology consists of: 1) an association with other auto- muscle. The inflammatory cell infiltrate is predominantly immune diseases; 2) serological tests which reflect an intrafascicular (endomysial) surrounding muscle fibres altered immune state; and 3) the responsiveness of rather than in the interfascicular septa, though perivascular polymyositis and dermatomyositis, if not of the inclusion infiltrates may also be found; the cellular infiltrate consists body variety, to immunotherapy.2 Polymyositis may rarely mainly of lymphocytes, plasma cells and macrophages.